Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Luu Pham

Pulmonary Disease Baltimore, MD Medical Doctor

NPI 1205037256 CMS profile 995583

5501 Hopkins Bayview Cir, 4Th Floor, Baltimore, MD 21224

Open in the dashboard

General payments

$2,531

23 records reported · program years 2021–2025

Research payments

$158,174

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$293,123 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Luu Pham of Baltimore, MD is reported in the CMS Open Payments database as having received $2,531 across 23 general payments and $158,174 in research payments paid to them. Separately, studies naming them as principal investigator received $293,123 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $580 6
2024 General $521 7
2024 Research $158,174 1
2023 General $424 5
2022 General $221 2
2021 General $785 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luu Pham
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Luu Pham were reported at $580. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Luu Pham Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $785 $269 $68–$1,072 $132
2022 $221 $390 $100–$1,457 $149
2023 $424 $419 $114–$1,659 $160
2024 $521 $476 $123–$1,818 $164
2025 $580 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Inspire Medical Systems, Inc. $2,006 16 payments
  2. LivaNova USA, Inc. $251 2 payments
  3. Respicardia, Inc. $191 3 payments
  4. Itamar Medical Inc $82 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,872 22 payments
  2. Travel and Lodging $659 1 payment
Products named General payments · program years 2021–2025
  1. INSPIRE $1,082 13 payments
  2. Inspire Upper Airway Stimulation System $924 3 payments
  3. THN Sleep Therapy $251 2 payments
  4. remede System $191 3 payments
  5. WatchPAT $82 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Itamar Medical Inc $158,174 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

34

Median for Critical Care (Intensivists): 406

Drug cost

$1,578

Median for Critical Care (Intensivists): $197,260

Branded share of claims

32.4%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine Sulfate Generic 12 $736
Ropinirole Er Ropinirole Hcl Brand 11 $720
Gabapentin Generic 11 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$31,753

Medicare's payments for the services billed

Medicare patients

269

Average age 71

Services billed

447

126 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 46%
Diabetes 44%
Depression 37%
Heart failure 35%
Chronic kidney disease 33%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record